KR102800305B1 - Cd47 신호전달 경로의 저해제로서의 1,2,4-옥사다이아졸 화합물 - Google Patents
Cd47 신호전달 경로의 저해제로서의 1,2,4-옥사다이아졸 화합물 Download PDFInfo
- Publication number
- KR102800305B1 KR102800305B1 KR1020207020398A KR20207020398A KR102800305B1 KR 102800305 B1 KR102800305 B1 KR 102800305B1 KR 1020207020398 A KR1020207020398 A KR 1020207020398A KR 20207020398 A KR20207020398 A KR 20207020398A KR 102800305 B1 KR102800305 B1 KR 102800305B1
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- compound
- delete delete
- cooh
- conh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020257013071A KR20250057146A (ko) | 2018-01-12 | 2019-01-11 | Cd47 신호전달 경로의 저해제로서의 1,2,4-옥사다이아졸 화합물 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841001438 | 2018-01-12 | ||
| IN201841001438 | 2018-01-12 | ||
| PCT/IB2019/050219 WO2019138367A1 (en) | 2018-01-12 | 2019-01-11 | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257013071A Division KR20250057146A (ko) | 2018-01-12 | 2019-01-11 | Cd47 신호전달 경로의 저해제로서의 1,2,4-옥사다이아졸 화합물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200108846A KR20200108846A (ko) | 2020-09-21 |
| KR102800305B1 true KR102800305B1 (ko) | 2025-04-28 |
Family
ID=67213573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207020398A Active KR102800305B1 (ko) | 2018-01-12 | 2019-01-11 | Cd47 신호전달 경로의 저해제로서의 1,2,4-옥사다이아졸 화합물 |
| KR1020257013071A Pending KR20250057146A (ko) | 2018-01-12 | 2019-01-11 | Cd47 신호전달 경로의 저해제로서의 1,2,4-옥사다이아졸 화합물 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257013071A Pending KR20250057146A (ko) | 2018-01-12 | 2019-01-11 | Cd47 신호전달 경로의 저해제로서의 1,2,4-옥사다이아졸 화합물 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11274123B2 (https=) |
| EP (1) | EP3737401A4 (https=) |
| JP (2) | JP7438955B2 (https=) |
| KR (2) | KR102800305B1 (https=) |
| CN (1) | CN111601801A (https=) |
| AU (2) | AU2019206438B2 (https=) |
| BR (1) | BR112020014202A2 (https=) |
| CA (1) | CA3087841A1 (https=) |
| CU (1) | CU24643B1 (https=) |
| EA (1) | EA202091267A1 (https=) |
| IL (1) | IL275952B2 (https=) |
| MX (1) | MX2020007383A (https=) |
| MY (1) | MY200800A (https=) |
| PH (1) | PH12020551062A1 (https=) |
| SG (1) | SG11202005992XA (https=) |
| WO (1) | WO2019138367A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737401A4 (en) * | 2018-01-12 | 2021-09-15 | Aurigene Discovery Technologies Limited | 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH |
| JP7623279B2 (ja) * | 2018-11-08 | 2025-01-28 | オーリジーン オンコロジー リミテッド | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
| CN114761041A (zh) | 2019-07-16 | 2022-07-15 | 吉利德科学公司 | Hiv疫苗及其制备和使用方法 |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| KR20220091576A (ko) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| KR20260017503A (ko) | 2020-02-14 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| KR20230157388A (ko) | 2021-03-12 | 2023-11-16 | 멘두스 비.브이. | 백신접종의 방법 및 cd47 차단의 용도 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR102690136B1 (ko) * | 2021-06-30 | 2024-07-31 | 연세대학교 산학협력단 | 바이러스 및 박테리아의 중복 감염 치료용 조성물 |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4452415B1 (en) | 2021-12-22 | 2026-02-25 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025083628A1 (en) | 2023-10-19 | 2025-04-24 | Aurigene Oncology Limited | Pharmaceutically acceptable salt of a cd47-sirp alpha pathway inhibitor |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250339404A1 (en) | 2024-05-03 | 2025-11-06 | Aurigene Oncology Limited | COMBINATION THERAPY USING A CD47-SIRP alpha BLOCKING AGENT AND AZACITIDINE |
| WO2025229631A2 (en) | 2024-05-03 | 2025-11-06 | Aurigene Oncology Limited | A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| US8748627B2 (en) * | 2006-02-15 | 2014-06-10 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| HRP20221260T1 (hr) | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| HRP20181052T1 (hr) * | 2013-09-06 | 2018-09-07 | Aurigene Discovery Technologies Limited | Derivati 1,2,4-oksadiazola kao imunomodulatori |
| ITTO20130731A1 (it) | 2013-09-09 | 2015-03-10 | Indesit Co Spa | Muffola di un forno nella quale sono fissate delle guide |
| NZ734650A (en) * | 2015-03-10 | 2023-07-28 | Aurigene Oncology Ltd | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| EP3267985A4 (en) * | 2015-03-10 | 2018-07-25 | Aurigene Discovery Technologies Limited | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| BR112017019306A2 (pt) * | 2015-03-10 | 2018-05-08 | Aurigene Discovery Technologies Limited | compostos de 1,3,4-oxadiazol e tiadiazol como imunomoduladores |
| CN104804093A (zh) | 2015-05-27 | 2015-07-29 | 江苏春申堂药业有限公司 | 一种针对cd47的单域抗体 |
| NZ741324A (en) | 2015-09-21 | 2021-09-24 | Erasmus Univ Medical Center | Anti-cd47 antibodies and methods of use |
| JP2019502753A (ja) * | 2015-12-23 | 2019-01-31 | ムーンショット ファーマ エルエルシー | ナンセンス変異依存ｍＲＮＡ分解機構の抑制による免疫応答の誘導法 |
| EP3243522A1 (en) | 2016-05-10 | 2017-11-15 | Université Pierre et Marie Curie (Paris 6) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death |
| DK3454879T3 (da) | 2016-05-10 | 2022-03-14 | Inst Nat Sante Rech Med | Hidtil ukendte forbindelser og farmaceutisk anvendelse deraf i behandlingen af kræft |
| WO2018047143A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
| WO2018047139A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Compounds as modulators of tigit signalling pathway |
| MY205585A (en) | 2016-10-20 | 2024-10-28 | Aurigene Oncology Ltd | Dual inhibitors of vista and pd-1 pathways |
| EP3737401A4 (en) | 2018-01-12 | 2021-09-15 | Aurigene Discovery Technologies Limited | 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH |
| JP7623279B2 (ja) * | 2018-11-08 | 2025-01-28 | オーリジーン オンコロジー リミテッド | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
-
2019
- 2019-01-11 EP EP19738566.9A patent/EP3737401A4/en active Pending
- 2019-01-11 MX MX2020007383A patent/MX2020007383A/es unknown
- 2019-01-11 BR BR112020014202-6A patent/BR112020014202A2/pt unknown
- 2019-01-11 IL IL275952A patent/IL275952B2/en unknown
- 2019-01-11 WO PCT/IB2019/050219 patent/WO2019138367A1/en not_active Ceased
- 2019-01-11 AU AU2019206438A patent/AU2019206438B2/en active Active
- 2019-01-11 KR KR1020207020398A patent/KR102800305B1/ko active Active
- 2019-01-11 KR KR1020257013071A patent/KR20250057146A/ko active Pending
- 2019-01-11 JP JP2020538785A patent/JP7438955B2/ja active Active
- 2019-01-11 MY MYPI2020003578A patent/MY200800A/en unknown
- 2019-01-11 CU CU2020000046A patent/CU24643B1/es unknown
- 2019-01-11 CA CA3087841A patent/CA3087841A1/en active Pending
- 2019-01-11 CN CN201980007859.6A patent/CN111601801A/zh active Pending
- 2019-01-11 US US16/245,860 patent/US11274123B2/en active Active
- 2019-01-11 EA EA202091267A patent/EA202091267A1/ru unknown
- 2019-01-11 SG SG11202005992XA patent/SG11202005992XA/en unknown
-
2020
- 2020-07-10 PH PH12020551062A patent/PH12020551062A1/en unknown
-
2021
- 2021-01-22 US US17/155,242 patent/US11560403B2/en active Active
-
2023
- 2023-01-05 US US18/150,246 patent/US12565515B2/en active Active
- 2023-12-14 JP JP2023211350A patent/JP7698699B2/ja active Active
-
2024
- 2024-03-04 AU AU2024201411A patent/AU2024201411B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11560403B2 (en) | 2023-01-24 |
| CU20200046A7 (es) | 2021-03-11 |
| MY200800A (en) | 2024-01-16 |
| CN111601801A (zh) | 2020-08-28 |
| EA202091267A1 (ru) | 2020-11-03 |
| AU2024201411A1 (en) | 2024-03-21 |
| US11274123B2 (en) | 2022-03-15 |
| KR20200108846A (ko) | 2020-09-21 |
| JP7438955B2 (ja) | 2024-02-27 |
| PH12020551062A1 (en) | 2021-09-01 |
| JP2021514345A (ja) | 2021-06-10 |
| IL275952B2 (en) | 2026-01-01 |
| EP3737401A1 (en) | 2020-11-18 |
| WO2019138367A1 (en) | 2019-07-18 |
| SG11202005992XA (en) | 2020-07-29 |
| US20230144653A1 (en) | 2023-05-11 |
| CU24643B1 (es) | 2023-02-13 |
| US20190218252A1 (en) | 2019-07-18 |
| US12565515B2 (en) | 2026-03-03 |
| AU2019206438A1 (en) | 2020-07-02 |
| JP2024028989A (ja) | 2024-03-05 |
| KR20250057146A (ko) | 2025-04-28 |
| IL275952A (en) | 2020-08-31 |
| AU2019206438B2 (en) | 2023-12-07 |
| EP3737401A4 (en) | 2021-09-15 |
| US20210139536A1 (en) | 2021-05-13 |
| AU2024201411B2 (en) | 2026-04-23 |
| IL275952B1 (en) | 2025-09-01 |
| BR112020014202A2 (pt) | 2020-12-01 |
| JP7698699B2 (ja) | 2025-06-25 |
| CA3087841A1 (en) | 2019-07-18 |
| MX2020007383A (es) | 2020-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102800305B1 (ko) | Cd47 신호전달 경로의 저해제로서의 1,2,4-옥사다이아졸 화합물 | |
| KR102894264B1 (ko) | 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물 | |
| CN107405336A (zh) | 作为免疫调节剂的1,3,4‑噁二唑和噻二唑化合物 | |
| KR20170123338A (ko) | 면역조절제로서의 치료적 환식 화합물 | |
| KR20170125931A (ko) | 면역조절제로서의 3-치환된 1,3,4-옥사다이아졸 및 티아다이아졸 화합물 | |
| HK1243348A1 (zh) | 作为免疫调节剂的3-取代的-1，2，4-恶二唑和噻二唑化合物 | |
| JP2025063207A (ja) | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ | |
| EA044002B1 (ru) | 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47 | |
| EA049945B1 (ru) | 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200714 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220107 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240226 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241024 |
|
| PX0701 | Decision of registration after re-examination |
Patent event date: 20250122 Comment text: Decision to Grant Registration Patent event code: PX07013S01D |
|
| X701 | Decision to grant (after re-examination) | ||
| A107 | Divisional application of patent | ||
| GRNT | Written decision to grant | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20250421 |
|
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250421 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20250422 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |